USFDA completes inspection at Kopran's arm facility

25 Jan 2019 Evaluate

Kopran’s wholly owned subsidiary - Kopran Research Laboratories has been inspected by the United States Food and Drug Administration (USFDA) starting from January 21 till January 25, 20 l 9. The Inspection has been completed without issuance of any observation.

This will facilitate commencement of supplies of APIs to the US market once DMF's are filed and approved. The company has filed the DMF of Atenolol which is already reviewed and active.

Kopran is engaged in pharmaceutical business. The company’s business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.

Kopran Share Price

135.60 -4.10 (-2.93%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×